251
|
Abstract
Biomarkers are important for early detection of cancer, prognosis, response prediction, and detection of residual or relapsing disease. Special attention has been given to diagnostic markers for prostate cancer since it is thought that early detection and surgery might reduce prostate cancer-specific mortality. The use of prostate-specific antigen, PSA (KLK3), has been debated on the base of cohort studies that show that its use in preventive screenings only marginally influences mortality from prostate cancer. Many groups have identified alternative or additional markers, among which PCA3, in order to detect early prostate cancer through screening, to distinguish potentially lethal from indolent prostate cancers, and to guide the treatment decision. The large number of markers proposed has led us to the present study in which we analyze these indicators for their diagnostic and prognostic potential using publicly available genomic data. We identified 380 markers from literature analysis on 20,000 articles on prostate cancer markers. The most interesting ones appeared to be claudin 3 (CLDN3) and alpha-methysacyl-CoA racemase highly expressed in prostate cancer and filamin C (FLNC) and keratin 5 with highest expression in normal prostate tissue. None of the markers proposed can compete with PSA for tissue specificity. The indicators proposed generally show a great variability of expression in normal and tumor tissue or are expressed at similar levels in other tissues. Those proposed as prognostic markers distinguish cases with marginally different risk of progression and appear to have a clinically limited use. We used data sets sampling 152 prostate tissues, data sets with 281 prostate cancers analyzed by microarray analysis and a study of integrated genomics on 218 cases to develop a multigene score. A multivariate model that combines several indicators increases the discrimination power but does not add impressively to the information obtained from Gleason scoring. This analysis of 10 years of marker research suggests that diagnostic and prognostic testing is more difficult in prostate cancer than in other neoplasms and that we must continue to search for better candidates.
Collapse
|
252
|
Budkaew J, Chumworathayi B. Factors associated with decisions to attend cervical cancer screening among women aged 30-60 years in Chatapadung Contracting Medical Unit, Thailand. Asian Pac J Cancer Prev 2015; 15:4903-7. [PMID: 24998561 DOI: 10.7314/apjcp.2014.15.12.4903] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND This study aimed to identify factors associated with women's decisions to attend cervical cancer screening and to explore those linked with intention to attend in the coming year and to continue regular screening. MATERIALS AND METHODS A community based case-control study was conducted among woman 30-60 years of age in catchment area of Chatapadung Contracting Medical Unit (CCMU), networking of Khon Kaen Center Hospital, Thailand. Self-administered questionnaires were used to collect data, and in-depth interviews were then performed to explore in greater detail. RESULTS There were 195 participants. Only one third (32.3 %) had been screened for cervical cancer within the past 5 years. Some 67.7% reported that they had not been screened because they had no abnormal symptoms, single marital status, and no children. Only 10.6% of those never had screening intent to be screened within the next 12 months. High family income (adjusted OR=2.16, 95%CI=1.13-4.14), good attitude towards a Pap test (OR=1.87, 95%CI=1.09-4.23), and having received a recommendation from health care providers were important factors associated with decisions to attend cervical cancer screening (OR=1.73, 95%CI=1.01-4.63). From in-depth interviews, there were five reasons of their decisions to attend cervical cancer screening including yearly check-up, postpartum check-up, having abnormal symptom, encouragement by health care providers, and request from workplace. CONCLUSIONS High family income, good attitude towards a Pap test, and receiving proper recommendation by health care providers, were important factors associated with decision to have cervical cancer screening among women 30-60 years old. Trying to enhance these factors and reduce barriers regarding screening, may increase the coverage rate for cervical cancer screening in Thailand.
Collapse
Affiliation(s)
- Jiratha Budkaew
- Department of Social Medicine, Khon Kaen Center Hospital, Khon Kaen University, Khon Kaen, Thailand E-mail :
| | | |
Collapse
|
253
|
Hammer T, Lynge E, Djurhuus GW, Joensen JE, Køtlum JE, Hansen SÓ, Sander BB, Mogensen O, Rebolj M. Cervical cancer screening in the Faroe Islands. Acta Oncol 2015; 54:210-6. [PMID: 25495570 DOI: 10.3109/0284186x.2014.986287] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND The Faroe Islands have had nationally organised cervical cancer screening since 1995. Women aged 25-60 years are invited every third year. Participation is free of charge. Although several European overviews on cervical screening are available, none have included the Faroe Islands. Our aim was to provide the first description of cervical cancer screening, and to determine the screening history of women diagnosed with cervical cancer in the Faroe Islands. MATERIAL AND METHODS Screening data from 1996 to 2012 were obtained from the Diagnostic Centre at the National Hospital of the Faroe Islands. They included information on cytology and HPV testing whereas information on histology was not registered consistently. Process indicators were calculated, including coverage rate, excess smears, proportion of abnormal cytological samples, and frequency of HPV testing. Data on cervical cancer cases were obtained from the Faroese Ministry of Health Affairs. The analysis of the screening history was undertaken for cases diagnosed in 2000-2010. RESULTS A total of 52 457 samples were taken in 1996-2012. Coverage varied between 67% and 81% and was 71% in 2012. Excess smears decreased after 1999. At present, 7.0% of samples have abnormal cytology. Of all ASCUS samples, 76-95% were tested for HPV. A total of 58% of women diagnosed with cervical cancer did not participate in screening prior to their diagnosis, and 32% had normal cytology in the previous four years. CONCLUSION Despite the difficult geographical setting, the organised cervical cancer screening programme in the Faroe Islands has achieved a relatively high coverage rate. Nevertheless, challenges, e.g. consistent histology registration and sending reminders, still exist.
Collapse
Affiliation(s)
- Turið Hammer
- Department of Public Health, University of Copenhagen , Copenhagen K , Denmark
| | | | | | | | | | | | | | | | | |
Collapse
|
254
|
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015; 136:189-97. [PMID: 25579108 DOI: 10.1016/j.ygyno.2014.11.076] [Citation(s) in RCA: 379] [Impact Index Per Article: 42.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Revised: 11/21/2014] [Accepted: 11/22/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVES ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer in women ≥25years. This reports the 3-year end-of-study results comparing the performance of HPV primary screening to different screening and triage combinations. METHODS 42,209 women ≥25years were enrolled and had cytology and hrHPV testing. Women with abnormal cytology (≥atypical squamous cells of undetermined significance) and those HPV positive were referred to colposcopy. Women not reaching the study endpoint of CIN2+ entered the 3-year follow-up phase. RESULTS 3-year CIR of CIN3+ in cytology-negative women was 0.8% (95% CI; 0.5-1.1%), 0.3% (95% CI 0.1-0.7%) in HPV-negative women, and 0.3% (95% CI; 0.1-0.6%) in cytology and HPV negative women. The sensitivity for CIN3+ of cytology was 47.8% (95% CI; 41.6-54.1%) compared to 61.7% (95% CI; 56.0-67.5%) for the hybrid strategy (cytology if 25-29years and cotesting with cytology and HPV if ≥30years) and 76.1% (95% CI; 70.3-81.8%) for HPV primary. The specificity for CIN3+ was 97.1% (95% CI; 96.9-97.2%), 94.6% (95% CI; 94.4-94.8%), and 93.5% (95% CI; 93.3-93.8%) for cytology, hybrid strategy, and HPV primary, respectively. Although HPV primary detects significantly more cases of CIN3+ in women ≥25years than either cytology or hybrid strategy, it requires significantly more colposcopies. However, the number of colposcopies required to detect a single CIN3+ is the same as for the hybrid strategy. CONCLUSIONS HPV primary screening in women ≥25years is as effective as a hybrid screening strategy that uses cytology if 25-29years and cotesting if ≥30years. However, HPV primary screening requires less screening tests.
Collapse
Affiliation(s)
- Thomas C Wright
- Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
| | - Mark H Stoler
- Department of Pathology, University of Virginia, Charlottesville, VA, USA.
| | | | - Abha Sharma
- Roche Molecular Systems, Pleasanton, CA, USA.
| | - Guili Zhang
- Roche Molecular Systems, Pleasanton, CA, USA.
| | | |
Collapse
|
255
|
Oliveira MV, Guimarães MDC, França EB. Fatores associados a não realização de Papanicolau em mulheres quilombolas. CIENCIA & SAUDE COLETIVA 2014; 19:4535-44. [DOI: 10.1590/1413-812320141911.15642013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Accepted: 08/27/2013] [Indexed: 11/22/2022] Open
Abstract
O objetivo deste estudo foi analisar os fatores associados a não realização do exame de Papanicolaou entre as mulheres quilombolas residentes em Vitória da Conquista, Bahia. Foi utilizado delineamento de estudo transversal de base populacional, com inclusão de mulheres com idade de 18-64 anos. Foram realizadas análise descritiva e de associação univariada e multivariada utilizando modelo logístico multinomial. Mulheres que nunca realizaram o exame ou o realizaram há mais de três anos foram comparadas separadamente com aquelas que realizaram o exame há menos de três anos. De 348 mulheres incluídas na análise, 27,3% afirmaram nunca ter realizado o Papanicolaou. Foram associados de forma independente com nunca ter feito o exame: faixa etária de 18 a 29 anos e 50 a 59 anos, não ter instrução, não ter companheiro, buscar atendimento relacionado à saúde em unidades/estabelecimentos diferentes de seu local de residência e ter realizado exame clínico das mamas há três ou mais anos ou nunca tê-lo realizado. Os achados indicam uma necessidade de reflexão, com o objetivo de melhor enfrentamento dos fatores que se associam à não realização do exame Papanicolaou entre as mulheres quilombolas, sendo importante contemplar ações de prevenção para o câncer de colo uterino.
Collapse
|
256
|
The increased detection of cervical intraepithelial neoplasia when using a second biopsy at colposcopy. Gynecol Oncol 2014; 135:201-7. [DOI: 10.1016/j.ygyno.2014.08.040] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 08/19/2014] [Accepted: 08/28/2014] [Indexed: 11/22/2022]
|
257
|
Fabrizii M, Moinfar F, Jelinek HF, Karperien A, Ahammer H. Fractal analysis of cervical intraepithelial neoplasia. PLoS One 2014; 9:e108457. [PMID: 25302712 PMCID: PMC4193757 DOI: 10.1371/journal.pone.0108457] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Accepted: 08/13/2014] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Cervical intraepithelial neoplasias (CIN) represent precursor lesions of cervical cancer. These neoplastic lesions are traditionally subdivided into three categories CIN 1, CIN 2, and CIN 3, using microscopical criteria. The relation between grades of cervical intraepithelial neoplasia (CIN) and its fractal dimension was investigated to establish a basis for an objective diagnosis using the method proposed. METHODS Classical evaluation of the tissue samples was performed by an experienced gynecologic pathologist. Tissue samples were scanned and saved as digital images using Aperio scanner and software. After image segmentation the box counting method as well as multifractal methods were applied to determine the relation between fractal dimension and grades of CIN. A total of 46 images were used to compare the pathologist's neoplasia grades with the predicted groups obtained by fractal methods. RESULTS Significant or highly significant differences between all grades of CIN could be found. The confusion matrix, comparing between pathologist's grading and predicted group by fractal methods showed a match of 87.1%. Multifractal spectra were able to differentiate between normal epithelium and low grade as well as high grade neoplasia. CONCLUSION Fractal dimension can be considered to be an objective parameter to grade cervical intraepithelial neoplasia.
Collapse
Affiliation(s)
- Markus Fabrizii
- Institute of Biophysics, Centre for Physiological Medicine, Medical University of Graz, Graz, Austria
| | - Farid Moinfar
- Unit of Breast and Gynaecologic Pathology, Institute of Pathology, Medical University of Graz, Graz, Austria; Department of Pathology, Hospital of the Sisters of Charity, Linz, Austria
| | - Herbert F Jelinek
- Centre for Research in Complex Systems, Charles Sturt University, Albury, Australia; School of Community Health, Charles Sturt University, Albury, Australia
| | - Audrey Karperien
- School of Community Health, Charles Sturt University, Albury, Australia
| | - Helmut Ahammer
- Institute of Biophysics, Centre for Physiological Medicine, Medical University of Graz, Graz, Austria
| |
Collapse
|
258
|
Williams JH, Carter SM, Rychetnik L. 'Organised' cervical screening 45 years on: How consistent are organised screening practices? Eur J Cancer 2014; 50:3029-38. [PMID: 25282406 DOI: 10.1016/j.ejca.2014.09.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Revised: 09/04/2014] [Accepted: 09/05/2014] [Indexed: 11/25/2022]
Abstract
Organised screening programmes have been remarkably successful in reducing incidence and mortality from cervical cancer, while opportunistic screening varies in its effectiveness. Experts recommend that cervical screening or HPV testing be carried out only in the context of an organised programme. We sought to answer the following study questions: What does it mean for a cervical screening programme to be organised? Is there a place for opportunistic screening (in an organised programme)? We reviewed 154 peer-reviewed papers on organised and opportunistic approaches to cervical screening published between 1970 and 2014 to understand how the term 'organised' is used, formally and in practice. We found that despite broad recognition of a prescriptive definition of organisation, in practice the meaning of organisation is much less clear. Our review revealed descriptions of organised programmes that differ significantly from prescribed norms and from each other, and a variety of ways that opportunistic and organised programmes intersect. We describe the breadth of the variation in cervical cancer screening programmes and examine the relationships and overlaps between organised and opportunistic screening. Implications emerging from the review include the need to better understand the breadth of organisation in practice, the drivers and impacts of opportunistic screening and the impact of opportunistic screening on population programme outcomes. Appreciation of the complexity of cervical screening programmes will benefit both screeners and women as programmes are changed to reflect a partially vaccinated population, new evidence and new technologies.
Collapse
Affiliation(s)
- Jane H Williams
- Centre for Values, Ethics and the Law in Medicine (VELiM), K25, School of Public Health, The University of Sydney, Camperdown, NSW 2006, Australia.
| | - Stacy M Carter
- Centre for Values, Ethics and the Law in Medicine (VELiM), K25, School of Public Health, The University of Sydney, Camperdown, NSW 2006, Australia.
| | - Lucie Rychetnik
- School of Medicine, University of Notre Dame, NSW 2010, Australia; Centre for Values, Ethics and the Law in Medicine (VELiM), K25, School of Public Health, The University of Sydney, Camperdown, NSW 2006, Australia.
| |
Collapse
|
259
|
Posttreatment Assessment of Women at Risk of Developing High-Grade Cervical Disease. J Low Genit Tract Dis 2014; 18:338-43. [DOI: 10.1097/lgt.0000000000000012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
260
|
Das L, Sarkar T, Maiti AK, Naskar S, Das S, Chatterjee J. Integrated cervical smear screening using liquid based cytology and bioimpedance analysis. J Cytol 2014; 31:183-8. [PMID: 25745281 PMCID: PMC4349006 DOI: 10.4103/0970-9371.151127] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVE To minimize the false negativity in cervical cancer screening with Papanicolaou (Pap) test, there is a need to explore novel cytological technique and identification of unique and important cellular features from the perspectives of morphological as well as biophysical properties. MATERIALS AND METHODS The present study explores the feasibility of low-cost cervical monolayer techniques in extracting cyto-pathological features to classify normal and abnormal conditions. The cervical cells were also analyzed in respect to their electrical bioimpedance. RESULT The results show that newly developed monolayer technique for cervical smears is cost effective, capable of cyto-pathological evaluation. Electrical bioimpedance study evidenced distinction between abnormal and normal cell population at more than two order of magnitude difference. CONCLUSION The integration of bioimpedance observation along with the proposed low-cost monolayer technology could increase the efficiency of the cervical screening to a greater extent thereby reducing the rates of faulty diagnosis.
Collapse
Affiliation(s)
- Lopamudra Das
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India
| | - Tandra Sarkar
- Department of Radiology, Apollo Gleanengles Hospital, Midnapore, India
| | - Ashok K. Maiti
- Department of Pathology, Midnapore Medical College and Hospital, Midnapore, India
| | - Sukla Naskar
- Department of Pathology, Calcutta National Medical College, Kolkata, West Bengal, India
| | - Soumen Das
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India
| | - Jyotirmoy Chatterjee
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India
| |
Collapse
|
261
|
Gudleviciene Z. Integration of human papillomavirus type 16 in cervical cancer cells. Open Med (Wars) 2014; 10:1-7. [PMID: 28352670 PMCID: PMC5152952 DOI: 10.1515/med-2015-0001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2013] [Accepted: 06/10/2014] [Indexed: 12/18/2022] Open
Abstract
Cervical cancer remains an important cause of women morbidity and mortality. The progression of cervical pathology correlates with the HPV integration into the host genome. However, the data on the viral integration status in cervical dysplasias are controversial. The aim of the current study was to evaluate the status of HPV integration in two types of cervical pathology - invasive and non invasive cervical cancer (e.g. carcinoma in situ). 156 women were included in the study: 66 women were diagnosed with invasive cervical cancer (CC) and 90 with non invasive cervical cancer (carcinoma in situ, CIS). 74.2% [95% PI: 63.64÷84.76] of specimens collected from women with diagnosed CC and 85.6% [95% PI: 85.53÷92.85] of CIS specimens were positive for HPV. The most prevalent HPV genotype in both groups was HPV16. To evaluate HPV integration, three selected HPV16 E2 gene fragments were analyzed by PCR. In the majority of CC and CIS specimens the amplification of all three HPV16 E2 gene fragments was observed. The episomal HPV16 form was detected in the majority of CC and CIS specimens. The deletion of all three HPV16 E2 gene fragments was detected in 9.4% of CC specimens and 2.2% of CIS specimens. Finally, integration status could not be used as diagnostical additional test to distinguish between invasive and non invasive cervical cancer.
Collapse
Affiliation(s)
- Zivile Gudleviciene
- Institute of Oncology, Vilnius University, Santariskiu str. 1, LT-08660 Vilnius, Lithuania
| |
Collapse
|
262
|
Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H, Goudeau A, Pigneaux de Laroche N, Rusch E, Giraudeau B. Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer 2014; 111:2187-96. [PMID: 25247320 PMCID: PMC4260034 DOI: 10.1038/bjc.2014.510] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Revised: 08/08/2014] [Accepted: 08/20/2014] [Indexed: 01/05/2023] Open
Abstract
Background: Cervical cancer screening coverage remains insufficient in most countries. Our objective was to assess whether in-home vaginal self-sampling with a dry swab for high-risk human papillomavirus (HR-HPV) testing is effective and cost-effective in increasing participation in cervical cancer screening. Methods: In March 2012, 6000 unscreened women aged 30–65 years, living in a French region covered by a screening programme, who had not responded to an initial invitation to have a Pap smear were equally randomised to three groups: ‘no intervention' ‘recall', women received a letter to have a Pap smear; and ‘self-sampling', women received a self-sampling kit to return to a centralised virology laboratory for PCR-based HPV testing. Results: Participation was higher in the ‘self-sampling' than in the ‘no intervention' group (22.5% vs 9.9%, P<0.0001; OR 2.64) and ‘recall' group (11.7%, P<0.0001; OR 2.20). In the ‘self-sampling' group, 320 used the self-sampling kit; for 44 of these women with positive HR-HPV test results, 40 had the recommended triage Pap smear. The ICER per extra screened woman was 77.8€ and 63.2€ for the ‘recall' and ‘self-sampling' groups, respectively, relative to the ‘no intervention' group. Conclusions: Offering an in-home, return-mail kit for vaginal self-sampling with a dry swab is more effective and cost-effective than a recall letter in increasing participation in cervical cancer screening.
Collapse
Affiliation(s)
- K Haguenoer
- 1] INSERM, U1153, Paris, France [2] Cancer Screening Department, CHRU de Tours, Tours 37000, France
| | - S Sengchanh
- Cancer Screening Department, CHRU de Tours, Tours 37000, France
| | - C Gaudy-Graffin
- 1] Department of Bacteriology and Virology, CHRU de Tours, Tours 37000, France [2] Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, Tours 37000, France [3] INSERM U966, Tours 37000, France
| | - J Boyard
- Cancer Screening Department, CHRU de Tours, Tours 37000, France
| | - R Fontenay
- Medico-Economic Evaluation Unit, CHRU de Tours, Tours 37000, France
| | - H Marret
- 1] Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, Tours 37000, France [2] Department of Gynaecology and Obstetrics, CHRU de Tours, Tours 37000, France
| | - A Goudeau
- 1] Department of Bacteriology and Virology, CHRU de Tours, Tours 37000, France [2] Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, Tours 37000, France [3] INSERM U966, Tours 37000, France
| | | | - E Rusch
- 1] Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, Tours 37000, France [2] Medico-Economic Evaluation Unit, CHRU de Tours, Tours 37000, France [3] Université François-Rabelais, Équipe émergente de recherche Éducation, Éthique, Santé, Tours, France
| | - B Giraudeau
- 1] INSERM, U1153, Paris, France [2] Université François-Rabelais de Tours, PRES Centre-Val de Loire Université, Tours 37000, France [3] CHRU de Tours, INSERM CIC1415, Tours 37000, France
| |
Collapse
|
263
|
Bentley J. Colposcopic management of abnormal cervical cytology and histology. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA 2014; 34:1188-1202. [PMID: 23231803 DOI: 10.1016/s1701-2163(16)35468-8] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVE To provide a guideline for managing abnormal cytology results after screening for cervical cancer, to clarify the appropriate algorithms for follow-up after treatment, and to promote the best possible care for women while ensuring efficient use of available resources. OUTCOMES Women with abnormal cytology are at risk of developing cervical cancer; appropriate triage and treatment will reduce this risk. This guideline will facilitate implementation of common standards across Canada, moving away from the current trend of individual guidelines in each province and territory. EVIDENCE Published literature was retrieved through searches of PubMed or Medline, CINAHL, and The Cochrane Library in October 2008 using appropriate controlled vocabulary (e.g., colposcopy, cervical dysplasia) and key words (e.g., colposcopy management, CIN, AGC, cervical dysplasia, LEEP, LLETZ, HPV testing, cervical dysplasia triage). Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date or language restrictions. Searches were updated on a regular basis and incorporated in the guideline to July 2012. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, and national and international medical specialty societies. Expert opinion from published peer-reviewed literature and evidence from clinical trials is summarized. Consensus opinion is outlined when evidence is insufficient. VALUES The quality of the evidence is rated using the criteria described by the Canadian Task Force on Preventive Health Care (Table 1). VALIDATION This guideline has been reviewed for accuracy from content experts in cytology, pathology, and cervical screening programs. Guideline content was also compared with similar documents from other organizations including the American Society for Colposcopy and Cervical Pathology, the British Society for Colposcopy and Cervical Pathology, and the European Cancer Network.
Collapse
|
264
|
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol 2014; 52:3996-4002. [PMID: 25210073 DOI: 10.1128/jcm.01962-14] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5+/6+ PCR, with a genotyping readout as an alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomavirus (HPV) types. LMNX is additionally provided with an internal control probe. Here, we present an analysis of the clinical performance of the LMNX using a sample panel and infrastructure provided by the international VALGENT (Validation of Genotyping Tests) project. This panel consisted of cervical specimens from approximately 1,000 women attending routine screening, "enriched" with 300 women with abnormal cytology. Cases were defined as women classified with cervical intraepithelial neoplasia (CIN) grade 2+ (CIN2+) (n = 102) or CIN3+ (n = 55) within the previous 18 months. Controls were women who had normal cytology results over two subsequent screening rounds at a 3-year interval (n = 746). The GP5+/6+-PCR EIA (EIA) was used as a comparator assay and showed sensitivities of 94.1% and 98.2% for CIN2+ and CIN3+, respectively, with a clinical specificity of 92.4% among women aged ≥ 30 years. The LMNX demonstrated clinical sensitivities of 96.1% for CIN2+ and of 98.2% for CIN3+ and a clinical specificity of 92.6% for women aged ≥ 30 years. The LMNX and EIA were in high agreement (Cohen's kappa = 0.969) for the detection of 14 hrHPVs in aggregate, and no significant difference was observed (McNemar's P = 0.629). The LMNX internal control detected 0.6% inadequate specimens. Based on our study results, we consider the LMNX, similarly to the EIA, useful for HPV-based cervical cancer screening.
Collapse
|
265
|
Petry KU, Wörmann B, Schneider A. Benefits and risks of cervical cancer screening. Oncol Res Treat 2014; 37 Suppl 3:48-57. [PMID: 25195832 DOI: 10.1159/000365059] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Karl U Petry
- Frauenklinik, Klinikum Wolfsburg, Wolfsburg, Germany
| | | | | |
Collapse
|
266
|
Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 2014; 31 Suppl 7:H59-70. [PMID: 24332298 DOI: 10.1016/j.vaccine.2013.03.029] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 02/28/2013] [Accepted: 03/05/2013] [Indexed: 11/17/2022]
Abstract
We present a review of current cervical cancer screening practices, the implementation status of vaccination against human papillomaviruses (HPV) and available data concerning the burden of HPV infection and HPV type-specific distribution in 16 Central and Eastern European countries: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia and the Former Yugoslav Republic (FYR) of Macedonia. Since published data were relatively scarce, two detailed surveys were conducted during August-October 2011 and in January 2013 to obtain relevant and updated information. The mean prevalence of HPV infection in 8610 women with normal cervical cytology from the region was 12.6%, with HPV16 being the most frequent HPV type. The overall HPV DNA prevalence in women with high-grade cervical lesions was 78.1%. HPV DNA was found in 86.6% of cervical cancers; the combined prevalence of HPV16/18 among HPV positive cases was 87.5%. The overall HPV DNA prevalence in genital warts and laryngeal papillomas was 94.8% and 95.2%, respectively, with HPV6 and HPV11 being the most frequent types. Opportunistic and organized cervical screening, mainly based on conventional cytology, is performed in nine and seven countries in the region, respectively, with the proposed age of the start of screening ranging from 20 to 30 years and the estimated coverage ranging from a few percent to over 70%. At least one of the current HPV prophylactic vaccines is registered in all Central and Eastern European countries except Montenegro. Only Bulgaria, Czech Republic, FYR Macedonia, Latvia, Romania and Slovenia have actually integrated HPV vaccination into their national immunization programme and currently provide routine vaccination free of charge to the primary target population. The key reasons for lack of implementation of HPV vaccination into the national immunization programme are high vaccine cost and negative public perception. This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in the Central and Eastern Europe and Central Asia Region" Vaccine Volume 31, Supplement 7, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.
Collapse
Affiliation(s)
- Mario Poljak
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
| | - Katja Seme
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Polona J Maver
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Boštjan J Kocjan
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - Kate S Cuschieri
- Specialist Virology Centre, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
| | - Svetlana I Rogovskaya
- Department of Obstetrics and Gynecology, Russian Medical Academy of Post-Graduate Education, Moscow, Russia
| | - Marc Arbyn
- Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium; Laboratory for Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
| | - Stina Syrjänen
- Department of Oral Pathology and Oral Radiology, Institute of Dentistry and Medicine Research Laboratory, University of Turku, Turku, Finland
| |
Collapse
|
267
|
Spinillo A, Gardella B, Chiesa A, Cesari S, Alberizzi P, Silini EM. Diagnostic accuracy of colposcopy in relation to human papillomavirus genotypes and multiple infection. Gynecol Oncol 2014; 134:527-33. [PMID: 25026638 DOI: 10.1016/j.ygyno.2014.07.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2014] [Revised: 07/04/2014] [Accepted: 07/06/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The aim of this study is to evaluate the diagnostic accuracy of colposcopy for cervical intraepithelial neoplasia grade 3 or worse (CIN3+) in relation to the detection of human papillomavirus (HPV) type 16 and multiple HPV infection. METHODS A cohort study of 2526 subjects attending a colposcopic service because of cytological abnormalities. HPV genotypes were identified using the INNO-LIPA genotyping system. RESULTS The final colposcopic/pathological diagnoses were as follows: 1282 (50.8%) negative, 709 (28.1%) CIN1, 169 (6.7%) CIN2, 318 (12.6%) CIN3 and 48 (1.9%) invasive cervical cancer, respectively. Among women with ASCUS/LSIL, assuming any colposcopic abnormality as a cut-off, there were no significant differences in the sensitivities (83.8%, 95% CI=76-89.6 as compared to 84.1%, 95% CI=73.2-91.1, p=0.9) and ROC curves (0.61, 95% CI=0.58-0.65 as compared to 0.59, 95% CI=0.54-0.64, p=0.5) in the detection of CIN3+ lesions between subjects with single and multiple high-risk infection, and between subjects infected by HPV16 (83.1%, 95% CI=73.7-89.7, ROC=0.59, 95% CI=0.54-063) or other high-risk HPVs (84.7%, 95% CI=75.6-90.8, ROC=0.62, 95% CI=0.58-0.66, p=0.8 and p=0.6 compared to HPV16). After correction for confounders, the odds ratios of CIN3+ associated with any abnormal colposcopic findings were 2.47 (95%CI=1.44-4.23, p=0.001) among HPV16 positive, 3.34 (95% CI=2.16-5.42, p<0.001) among other high-risk HPVs and 1.3 (95% CI=0.72-2.48, p=0.36) among subjects with negative/low-risk HPVs. CONCLUSION In routine clinical practice, multiple infection or HPV16 positivity did not affect colposcopic accuracy in the diagnosis of CIN3+ lesions. The sensitivity of colposcopy was poor among subjects who were uninfected or infected by low-risk HPV genotypes.
Collapse
Affiliation(s)
- Arsenio Spinillo
- Department of Obstetrics and Gynecology, University of Pavia, IRCCS Fondazione Policlinico San Matteo, Italy.
| | - Barbara Gardella
- Department of Obstetrics and Gynecology, University of Pavia, IRCCS Fondazione Policlinico San Matteo, Italy
| | - Alessia Chiesa
- Department of Obstetrics and Gynecology, University of Pavia, IRCCS Fondazione Policlinico San Matteo, Italy
| | - Stefania Cesari
- Department of Pathology, University of Pavia, IRCCS Fondazione Policlinico San Matteo, Italy
| | - Paola Alberizzi
- Department of Pathology, University of Pavia, IRCCS Fondazione Policlinico San Matteo, Italy
| | - Enrico Maria Silini
- Department of Biomedical, Biotechnological and Translational Sciences, Unit of Surgical Pathology and Center for Molecular and Translational Oncology (COMT), University of Parma, Italy
| |
Collapse
|
268
|
Boldrini NT, Freitas LB, Coutinho AR, Loureiro FZ, Spano LC, Miranda AE. High-grade cervical lesions among women attending a reference clinic in Brazil: associated factors and comparison among screening methods. PLoS One 2014; 9:e102169. [PMID: 25019210 PMCID: PMC4094527 DOI: 10.1371/journal.pone.0102169] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2014] [Accepted: 06/16/2014] [Indexed: 11/25/2022] Open
Abstract
Background Although screening for cervical cancer is recommended for women in most countries, the incidence of cervical cancer is greater in developing countries. Our goal was to determine the prevalence and factors associated with high-grade lesions/cervical cancer among women attending a reference clinic in Brazil and evaluate the correlation of histology with cytology, colposcopy and the high-risk HPV (HR-HPV) tests. Methods A cross-sectional study of women attending a colposcopy clinic was carried out. The patients were interviewed to collect demographic, epidemiological and clinical data. Specimens were collected for cervical cytology, Chlamydia trachomatis and HPV testing using the Hybrid Capture (HC) and PCR tests. Colposcopy was performed for all patients and biopsy for histology when cell abnormalities or cervical intraepithelial neoplasia (CIN) were present. Results A total of 291 women participated in the study. The median age was 38 years (DIQ: 30–48 years). The prevalence of histologically confirmed high-grade lesions/cervical cancer was 18.2% (95%, CI: 13.8%–22.6%), with 48 (16.5%) cases of CIN-2/CIN-3 and 5 (1.7%) cases of invasive carcinoma. In the final logistic regression model, for ages between 30 and 49 years old [OR = 4.4 (95%: 1.01–19.04), history of smoking [OR = 2.4 (95%, CI: 1.14–5.18)], practice of anal intercourse [OR = 2.4 (95%, CI: 1.10–5.03)] and having positive HC test for HR-HPV [OR = 11.23 (95%, CI: 4 0.79–26, 36)] remained independently associated with high-grade lesions/cervical cancer. A total of 64.7% of the cases CIN-3\Ca in situ were related to HPV-16. Non-oncogenic HPV were only found in CIN-1 biopsy results. Compared to histology, the sensitivity of cytology was 31.8%, the specificity 95.5%; the sensitivity of colposcopy for high-grade lesions/cervical cancer was 51.0%, specificity was 91.4% and the concordance with HPV testing was high. Conclusions The results confirm an association of HR-HPV with precursor lesions for cervical cancer. These data emphasize that cytological screening to detect precursor lesions is still important in some regions and that HR-HPV should be included for screening.
Collapse
Affiliation(s)
- Neide T. Boldrini
- Post-Graduate Program in Infectious Diseases, Federal University of Espirito Santo (Universidade Federal do Espírito Santo – UFES), Vitória-Espírito Santo (ES), Brazil
| | - Luciana B. Freitas
- Post-Graduate Program in Infectious Diseases, Federal University of Espirito Santo (Universidade Federal do Espírito Santo – UFES), Vitória-Espírito Santo (ES), Brazil
| | - Amanda R. Coutinho
- Post-Graduate Program in Infectious Diseases, Federal University of Espirito Santo (Universidade Federal do Espírito Santo – UFES), Vitória-Espírito Santo (ES), Brazil
| | - Flavia Z. Loureiro
- Post-Graduate Program in Infectious Diseases, Federal University of Espirito Santo (Universidade Federal do Espírito Santo – UFES), Vitória-Espírito Santo (ES), Brazil
| | - Liliana C. Spano
- Post-Graduate Program in Infectious Diseases, Federal University of Espirito Santo (Universidade Federal do Espírito Santo – UFES), Vitória-Espírito Santo (ES), Brazil
| | - Angélica E. Miranda
- Post-Graduate Program in Infectious Diseases, Federal University of Espirito Santo (Universidade Federal do Espírito Santo – UFES), Vitória-Espírito Santo (ES), Brazil
- * E-mail:
| |
Collapse
|
269
|
Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Prev Med 2014; 64:108-13. [PMID: 24736093 DOI: 10.1016/j.ypmed.2014.04.011] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Revised: 03/10/2014] [Accepted: 04/04/2014] [Indexed: 11/22/2022]
Abstract
OBJECTIVES High attendance rates in cervical screening are essential for effective cancer prevention. Offering HPV self-sampling to non-responders increases participation rates. The objectives of this study were to determine why non-responders do not attend regular screening, and why they do or do not participate when offered a self-sampling device. METHODS A questionnaire study was conducted in the Netherlands from October 2011 to December 2012. A total of 35,477 non-responders were invited to participate in an HPV self-sampling study; 5347 women did opt out. Finally, 30,130 women received a questionnaire and self-sampling device. RESULTS The analysis was based on 9484 returned questionnaires (31.5%) with a self-sample specimen, and 682 (2.3%) without. Among women who returned both, the main reason for non-attendance to cervical screening was that they forgot to schedule an appointment (3068; 32.3%). The most important reason to use the self-sampling device was the opportunity to take a sample in their own time-setting (4763; 50.2%). A total of 30.9% of the women who did not use the self-sampling device preferred after all to have a cervical smear taken instead. CONCLUSIONS Organisational barriers are the main reason for non-attendance in regular cervical screening. Important reasons for non-responders to the regular screening to use a self-sampling device are convenience and self-control.
Collapse
|
270
|
Videla S, Darwich L, Cañadas M, Clotet B, Sirera G. Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages. Expert Rev Anti Infect Ther 2014; 12:947-57. [PMID: 24865412 DOI: 10.1586/14787210.2014.922872] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Oral human papillomavirus (HPV) infections are less prevalent than genital and anal infections. However, the incidence of oropharyngeal squamous cell carcinomas has increased significantly over the last 2 decades in several countries. At least 90% of these cancers are associated with oncogenic type HPV16. Oral HPV infections are notably more frequent in men than in women, and the incidence of HPV-positive oropharyngeal squamous cell carcinomas has increased, predominantly among mid-adult men. Nevertheless, little is known about the progression of oral HPV infection to cancer, and it remains unclear which medical interventions should be applied to modify the natural history of the disease. This narrative review aimed at non-experts in HPV infection provides an update on oral HPV infection and its clinical management in men. Furthermore, using the cervix as a reference anatomical site, the lessons learned from investigations on cervical HPV infection are also addressed.
Collapse
Affiliation(s)
- Sebastián Videla
- Lluita Contra La SIDA Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona (Barcelona), Spain
| | | | | | | | | |
Collapse
|
271
|
|
272
|
Castro B, Ribeiro DP, Oliveira J, Pereira MB, Sousa JCD, Yaphe J. [Cervical cancer screening: target age bracket, screening frequency and screening method: review of recent evidence and comparison with the Portuguese performance indicator]. CIENCIA & SAUDE COLETIVA 2014; 19:1113-22. [PMID: 24820594 DOI: 10.1590/1413-81232014194.18002012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Accepted: 09/27/2012] [Indexed: 11/22/2022] Open
Abstract
The scope of this review was to assess the strength of evidence of Portuguese performance indicators on Cervical Cancer screening: (1) age group of the women that should be screened for cervical cancer; (2) frequency of screening; and (3) the best method for screening. The following MeSH terms were searched: vaginal smears, age groups, periodicity, methods, uterine cervical cancer. Articles not reflecting the study objectives or not available in English, Portuguese or Spanish were excluded. The SORT classification was used to rate the articles selected.Of the 197 articles found, 9 that met all study criteria were selected for inclusion in this review. These included 1 systematic review, 1 randomized controlled clinical trial, 2 retrospective studies and 5 clinical guidelines. The authors also chose to include 4 clinical guidelines and two systematic reviews relevant to the Portuguese population even though they did not appear in the initial search of the literature. The studies suggest screening women between the ages of 21 to 25 years and 65 years of age, once every three years using conventional cytology. There is still controversy regarding the three objectives of this study (target age bracket, screening frequency and screening method).
Collapse
Affiliation(s)
- Bárbara Castro
- Unidade de Saúde Familiar Manuel Rocha Peixoto, Braga, Minho, Portugal,
| | | | - Joana Oliveira
- Unidade de Saúde Familiar Manuel Rocha Peixoto, Braga, Minho, Portugal,
| | - Miguel Basto Pereira
- Instituto de Ciências da Vida e da Saúde, Escola de Ciências da Saúde, Universidade do Minho
| | - Jaime Correia de Sousa
- Instituto de Ciências da Vida e da Saúde, Escola de Ciências da Saúde, Universidade do Minho
| | - John Yaphe
- Instituto de Ciências da Vida e da Saúde, Escola de Ciências da Saúde, Universidade do Minho
| |
Collapse
|
273
|
Liu Y, Qiu HF, Tang Y, Chen J, Lv J. Pregnancy Outcome after the Treatment of Loop Electrosurgical Excision Procedure or Cold-Knife Conization for Cervical Intraepithelial Neoplasia. Gynecol Obstet Invest 2014; 77:240-4. [DOI: 10.1159/000360538] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Accepted: 02/10/2014] [Indexed: 11/19/2022]
|
274
|
Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer 2014; 110:1841-6. [PMID: 24518600 PMCID: PMC3974083 DOI: 10.1038/bjc.2014.65] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Revised: 01/14/2014] [Accepted: 01/15/2014] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND To quantify the benefits (cancer prevention and down-staging) and harms (recall and excess treatment) of cervical screening starting from age 20 years rather than from age 25 years. METHODS We use routine screening and cancer incidence statistics from Wales (for screening from age 20 years) and England (screening from 25 years), and unpublished data from the National Audit of Invasive Cervical Cancer to estimate the number of: screening tests, women with abnormal results, referrals to colposcopy, women treated, and diagnoses of micro-invasive (stage 1A) and frank-invasive (stage IB+) cervical cancers (under three different scenarios) in women invited for screening from age 20 years and from 25 years. RESULTS Inviting 100,000 women from age 20 years yields an additional: 119,000 screens, 20,000 non-negative results, 8000 colposcopy referrals, and an extra 3000 women treated when compared with inviting from age 25 years. Screening from age 20 years prevents between three and nine frank invasive cancers and between 0 and 23 cancers in total (depending on the scenario). A cumulative increase of nine stage IB+ cancers corresponds to an annual rate increase of 0.9 per 100,000 women aged 20-29 years. CONCLUSIONS To prevent one frank invasive cancer, one would need to do between 12,500 and 40,000 additional screening tests in the age group 20-24 years and treat between 300 and 900 women.
Collapse
Affiliation(s)
- R Landy
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Bart's and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - H Birke
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Bart's and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - A Castanon
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Bart's and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - P Sasieni
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Bart's and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| |
Collapse
|
275
|
Arbyn M, Fabri V, Temmerman M, Simoens C. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006). PLoS One 2014; 9:e92615. [PMID: 24690620 PMCID: PMC3972167 DOI: 10.1371/journal.pone.0092615] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Accepted: 02/23/2014] [Indexed: 12/03/2022] Open
Abstract
Objective To assess the coverage for cervical cancer screening as well as the use of cervical cytology, colposcopy and other diagnostic and therapeutic interventions on the uterine cervix in Belgium, using individual health insurance data. Methods The Intermutualistic Agency compiled a database containing 14 million records from reimbursement claims for Pap smears, colposcopies, cervical biopsies and surgery, performed between 2002 and 2006. Cervical cancer screening coverage was defined as the proportion of women aged 25–64 that had a Pap smear within the last 3 years. Results Cervical cancer screening coverage was 61% at national level, for the target population of women between 25 and 64 years old, in the period 2004–2006. Differences between the 3 regions were small, but varied more substantially between provinces. Coverage was 70% for 25–34 year old women, 67% for those aged 35–39 years, and decreased to 44% in the age group of 60–64 years. The median screening interval was 13 months. The screening coverage varied substantially by social category: 40% and 64%, in women categorised as beneficiary or not-beneficiary of increased reimbursement from social insurance, respectively. In the 3-year period 2004–2006, 3.2 million screen tests were done in the target group consisting of 2.8 million women. However, only 1.7 million women got one or more smears and 1.1 million women had no smears, corresponding to an average of 1.88 smears per woman in three years of time. Colposcopy was excessively used (number of Pap smears over colposcopies = 3.2). The proportion of women with a history of conisation or hysterectomy, before the age of 65, was 7% and 19%, respectively. Conclusion The screening coverage increased slightly from 59% in 2000 to 61% in 2006. The screening intensity remained at a high level, and the number of cytological examinations was theoretically sufficient to cover more than the whole target population.
Collapse
Affiliation(s)
- Marc Arbyn
- Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
- * E-mail:
| | - Valérie Fabri
- Intermutualistic Agency (IMA/AIM), Brussels, Belgium
| | - Marleen Temmerman
- Department of Gynaecology and Obstetrics, Ghent University, Ghent, Belgium
- Director, Reproductive Health and Research, World Health Organization, Geneva, Switzerland
| | - Cindy Simoens
- Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
- Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium
| |
Collapse
|
276
|
[Cost-benefit analysis of a population-based cervical cancer screening program designed for Cantabria]. Semergen 2014; 40:296-304. [PMID: 24534799 DOI: 10.1016/j.semerg.2013.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2013] [Revised: 10/23/2013] [Accepted: 11/23/2013] [Indexed: 11/22/2022]
Abstract
INTRODUCTION Cervical cancer is the second most common cancer worldwide in women, with an annual mortality of 3.6 per 100.000 women in Spain. An opportunistic screening protocol is currently being developed in Cantabria. The objective of the study is to propose a population-based screening program in Cantabria and assess its cost-benefits. PATIENTS AND METHODS The population-based program design has been carried out according to the description of the natural course of cervical cancer and its incidence and mortality in Cantabria during 2000-2009. There have been some proposals to increase participation in the program and to evaluate its quality. Costs and benefits (direct and indirect) have been analyzed in several scenarios by modifying the frequency of tests (3-5 years), the age at which the program can be accessed (21, 25 or 30 years), the coverage of the program (60-80%), and discount rates (0-3-6%). RESULTS A program carried out with coverage of 80% and tests performed every 3 years generates annual costs of €893.000 (discount rate of 3%) compared to the current opportunistic protocol. Scenarios with tests performed every 5 years generate an annual benefit higher than €618.000, depending on the age of accessing the program. CONCLUSIONS Scenarios with coverage lower than 60% or with women over 30 years old having access to the program are not of interest because of the lower health benefits. However, performing tests every 5 years is more economically advantageous than every 3 years, with similar health benefits.
Collapse
|
277
|
Affiliation(s)
- Sandra D Isidean
- Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada H3A 1A2; Department of Oncology, McGill University, Montreal, QC, Canada H2W 1S6
| | - Eduardo L Franco
- Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada H3A 1A2; Department of Oncology, McGill University, Montreal, QC, Canada H2W 1S6.
| |
Collapse
|
278
|
Mistro AD, Frayle H, Ferro A, Callegaro S, Sole AD, Stomeo A, Cirillo E, Fedato C, Pagni S, Barzon L, Zorzi M. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women. J Med Screen 2014; 21:30-7. [DOI: 10.1177/0969141314522219] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective Cervical cancer screening by human papillomavirus (HPV) testing requires the use of additional triage and follow-up analyses. We evaluated women’s compliance with and the performance of this strategy in a routine setting. Setting Five cervical service screening programmes in North-East Italy. Methods Eligible women aged 25-64 invited for a new screening episode underwent HPV testing for high risk types (hrHPV by Hybrid Capture 2) and cytology triage. Women with positive HPV and cytology results were referred for colposcopy; women with positive HPV but negative cytology results were referred to 1-year repeat hrHPV testing. Results Of 46,694 women screened by HPV testing up to December 2011, 3,211 (6.9%) tested hrHPV positive; 45% of these had a positive triage cytology. Those with negative cytology were invited for 1-yr repeat testing. Compliance with invitation was 61.6% at baseline and 85.3% at 1-yr repeat. Rate of persistent hrHPV positivity was 58% (830/1,435). Colposcopy performed in women with a positive hrHPV test at 1-yr repeat accounted for 36% of all colposcopies performed within the screening programmes. Cumulatively, a histological high-grade lesion was detected in 276 women (5.9‰ detection rate), 234 at baseline (85%), and 42 (15%) at 1-yr repeat. Conclusions Compliance with hrHPV-based screening programmes was high both at baseline and at 1-yr repeat. Compared with the randomized trials, a higher proportion of triage cytology was read as positive, and only a small number of high-grade lesions were detected among the group of hrHPV positive cytology negative women who repeated testing 1-yr after baseline.
Collapse
Affiliation(s)
- Annarosa Del Mistro
- Immunology and Molecular Oncology Unit, Veneto Oncology Institute IOV IRCCS, Padova, Italy
| | - Helena Frayle
- Immunology and Molecular Oncology Unit, Veneto Oncology Institute IOV IRCCS, Padova, Italy
| | - Antonio Ferro
- Department of Prevention; Local Health Unit 17 Este-Monselice, Italy
| | | | | | - Anna Stomeo
- Department of Prevention; Local Health Unit 18 Rovigo, Italy
| | | | | | - Silvana Pagni
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Luisa Barzon
- Department of Molecular Medicine, University of Padova, Padova, Italy
| | | |
Collapse
|
279
|
Orlando G, Fasolo M, Mazza F, Ricci E, Esposito S, Frati E, Zuccotti GV, Cetin I, Gramegna M, Rizzardini G, Tanzi E. Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study. Hum Vaccin Immunother 2014; 10:986-94. [PMID: 24423757 PMCID: PMC4896517 DOI: 10.4161/hv.27682] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the main obstacles for a more widespread use of HPV vaccination in many countries. Data on the rate, risk factors, and HPV types in sexually active women could provide information for the evaluation of vaccination policies extended to broader age cohorts. Sexually active women aged 13–26 years enrolled in an Italian cohort study were screened for cervical HPV infections; HPV-DNA positive samples were genotyped by InnoLipa HPV Genotyping Extra or by RFLP genotype analysis. Among the 796 women meeting the inclusion criteria, 10.80% (95% CI 8.65–12.96) were HPV-DNA infected. Age >18 years, lifetime sexual partners >1, and history of STIs were associated to higher risk of HPV infection in the multivariable models adjusted for age, lifetime sexual partners, and time of sexual exposure. The global prevalence of the four HPV vaccine-types was 3.02% (95% CI 1.83–4.20) and the cumulative probability of infection from at least one vaccine-type was 12.82% in 26-years-old women and 0.78% in 18-years-old women. Our data confirm most of the previously reported findings on the risk factors for HPV infections. The low prevalence of the HPV vaccine-types found may be useful for the evaluation of the cost/efficacy and the cost/effectiveness of broader immunization programs beyond the 12-years-old cohort.
Collapse
Affiliation(s)
- Giovanna Orlando
- STD Unit; Infectious Diseases I; L Sacco University Hospital; Milan, Italy
| | - Michela Fasolo
- STD Unit; Infectious Diseases I; L Sacco University Hospital; Milan, Italy
| | - Francesca Mazza
- STD Unit; Infectious Diseases I; L Sacco University Hospital; Milan, Italy
| | - Elena Ricci
- Infectious Diseases I; L Sacco University Hospital; Milan, Italy
| | - Susanna Esposito
- Pediatric Clinic I; Department of Pathophysiology and Transplantation; University of Milan; Milan, Italy
| | - Elena Frati
- Department of Biomedical Sciences for Health; University of Milan; Milan, Italy
| | | | - Irene Cetin
- Gynaecology Unit; L Sacco University Hospital; Milan, Italy
| | - Maria Gramegna
- Unità Organizzativa Governo della Prevenzione e Tutela Sanitaria; Direzione Generale Sanità; Regione Lombardia; Milan, Italy
| | | | - Elisabetta Tanzi
- Department of Biomedical Sciences for Health; University of Milan; Milan, Italy
| | | |
Collapse
|
280
|
Richardson LA, Tota J, Franco EL. Optimizing technology for cervical cancer screening in high-resource settings. ACTA ACUST UNITED AC 2014; 6:343-353. [PMID: 26617667 DOI: 10.1586/eog.11.13] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although historically successful in reducing the burden of cervical cancer, Papanicolaou (Pap) testing faces numerous limitations. A growing body of evidence suggests that modern screening practice will benefit from primary screening for high-risk human papillomavirus (HPV) infection, the causative agent of cervical cancer. Molecular tests detecting the presence of HPV nucleic acids consistently demonstrate high sensitivity relative to Pap testing, and provide reliable, dichotomous results. Pap cytology is ideally suited to triage HPV-positive cases owing to its high test specificity, and the accuracy of cytological readings will be maximized in high-prevalence conditions. This algorithm of primary HPV testing with Pap triage has been shown to maintain the high sensitivity of HPV testing without compromising Pap cytology's strong ability to rule out falsely positive diagnoses. Given the anticipated decline of high-risk HPV-16 and -18 infections in the emergent post-HPV vaccination era, highly sensitive primary HPV testing is especially warranted. Novel screening technologies that identify HPV viral gene expression continue to emerge and seek to complement current HPV testing by identifying those women who may be at risk of progressive disease. How to best incorporate these new technologies into clinical practice presents our next great challenge. Implementation of novel algorithms for cervical screening is not a trivial task. Avoidance of exceedingly complex screening algorithms is an important priority.
Collapse
Affiliation(s)
- Lyndsay A Richardson
- Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montreal, QC, H2W 1S6, Canada
| | - Joseph Tota
- Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montreal, QC, H2W 1S6, Canada
| | - Eduardo L Franco
- Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montreal, QC, H2W 1S6, Canada
| |
Collapse
|
281
|
Bhattacharyya S, James R, Rimington H, Allen J, Lee L, Fox K, Masani ND, Lloyd G. Development of a National Echocardiography Quality Improvement Programme: insights into feasibility, uptake, and clinical utility. Eur Heart J Cardiovasc Imaging 2014; 15:747-52. [DOI: 10.1093/ehjci/jet280] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
282
|
5-Aminolevulinic acid-based fluorescence diagnostics of cervical preinvasive changes. Medicina (B Aires) 2014; 50:137-43. [DOI: 10.1016/j.medici.2014.08.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 06/03/2014] [Accepted: 06/03/2014] [Indexed: 12/29/2022] Open
|
283
|
Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, Joyce JC, Katsanos KH, Lopez A, de Xaxars TM, Toader E, Beaugerie L. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2014; 8:31-44. [PMID: 23721759 DOI: 10.1016/j.crohns.2013.04.006] [Citation(s) in RCA: 116] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 04/05/2013] [Indexed: 12/28/2022]
Abstract
The incidence of lymphoproliferative disorders (LD) is increasing in developed countries. Patients with inflammatory bowel disease (IBD) exposed to thiopurines are at additional risk of three specific forms of LD: Epstein-Barr-Virus-related post-transplant like LD, hepato-splenic T-cell lymphoma and post-mononucleosis lymphoproliferation. The risk of the two latter forms of LD can be reduced when considering specific immunosuppressive strategies in young males. It is still unclear whether the risk of uterine cervix abnormalities is increased in IBD women, irrespective of the use of immunosuppressants. Given the excess risk demonstrated in various other contexts of immunosuppression, it is currently recommended that all women with IBD, particularly those receiving immunosuppressants, strictly adhere to a screening program of cervical surveillance and undergo vaccination against HPV, when appropriate. Patients with IBD receiving immunosuppressants are at increased risk of skin cancers. The risk of non-melanoma skin cancer is notably increased in patients receiving thiopurines. Recent data suggest that the risk of melanoma is mildly increased in patients exposed to anti-TNF therapy. All IBD patients should adhere to a program of sun protection and dermatological surveillance, whose details should take into account the other non-IBD-related risk factors.
Collapse
Affiliation(s)
- Fernando Magro
- Gastroenterology Department, Centro Hospitalar S. João, Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal
| | - Laurent Peyrin-Biroulet
- Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, and Université Henri Poincaré 1,Vandoeuvre-lès-Nancy, France
| | - Harry Sokol
- Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine F-75012 and ERL 1057 INSERM/UMRS 7203, UPMC Univ Paris 06F-75005, Paris, France
| | - Xavier Aldeger
- Department of Gastroenterology of University Hospital Doctor Josep Trueta de Girona, Spain
| | - Antonia Costa
- Department of Gynecology and Obstetrics Department, Centro Hospitalar S. João, Portugal, and Faculty of Medicine, Porto University, Porto, Portugal
| | - Peter D Higgins
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Joel C Joyce
- Department of Dermatology, Medical College of Wisconsin, WI, USA
| | - Konstantinos H Katsanos
- Department of Internal Medicine & Hepato-Gastroenterology Unit, Medical School University of Ioannina, Ioannina, Greece
| | - Anthony Lopez
- Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, and Université Henri Poincaré 1,Vandoeuvre-lès-Nancy, France
| | | | - Elena Toader
- Gastroenterology and Hepatology Center, University Hospital Sf. Spiridon, and University of Medicine and Pharmacy Gr. T. Popa, Iasi, Romania
| | - Laurent Beaugerie
- Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine F-75012 and ERL 1057 INSERM/UMRS 7203, UPMC Univ Paris 06F-75005, Paris, France.
| |
Collapse
|
284
|
Salo H, Nieminen P, Kilpi T, Auranen K, Leino T, Vänskä S, Tiihonen P, Lehtinen M, Anttila A. Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland. Int J Cancer 2013; 135:204-13. [DOI: 10.1002/ijc.28646] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2013] [Accepted: 11/21/2013] [Indexed: 01/22/2023]
Affiliation(s)
- Heini Salo
- Department of Vaccination and Immune Protection; National Institute for Health and Welfare (THL); Helsinki Finland
| | - Pekka Nieminen
- Department of Obstetrics and Gynecology; Helsinki University Central Hospital; Espoo Finland
| | - Terhi Kilpi
- Department of Vaccination and Immune Protection; National Institute for Health and Welfare (THL); Helsinki Finland
| | - Kari Auranen
- Department of Vaccination and Immune Protection; National Institute for Health and Welfare (THL); Helsinki Finland
| | - Tuija Leino
- Department of Vaccination and Immune Protection; National Institute for Health and Welfare (THL); Helsinki Finland
| | - Simopekka Vänskä
- Department of Vaccination and Immune Protection; National Institute for Health and Welfare (THL); Helsinki Finland
- School of Health Sciences; University of Tampere; Tampere Finland
| | - Petri Tiihonen
- Department of Vaccination and Immune Protection; National Institute for Health and Welfare (THL); Helsinki Finland
| | - Matti Lehtinen
- School of Health Sciences; University of Tampere; Tampere Finland
| | - Ahti Anttila
- Mass Screening Registry, Finnish Cancer Registry; Helsinki Finland
| |
Collapse
|
285
|
Isidean SD, Coutlée F, Franco EL. cobas®4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Rev Mol Diagn 2013; 14:5-16. [DOI: 10.1586/14737159.2014.865521] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
286
|
Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and Trends in Human Papillomavirus-Related Diseases in Central and Eastern Europe and Central Asia. Vaccine 2013; 31 Suppl 7:H32-45. [DOI: 10.1016/j.vaccine.2013.02.071] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2012] [Revised: 01/28/2013] [Accepted: 02/11/2013] [Indexed: 10/25/2022]
|
287
|
Poljak M, Rogovskaya SI, Kesić V, Bray F, Berkhof J, Seme K, Brotons M, Castellsagué X, Syrjänen S, Arbyn M, Bosch FX. Recommendations for Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine 2013; 31 Suppl 7:H80-2. [DOI: 10.1016/j.vaccine.2013.04.038] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
288
|
Bosgraaf RP, Siebers AG, De Hullu JA, Massuger LFAG, Bulten J, Bekkers RLM, Melchers WJG. The current position and the future perspectives of cervical cancer screening. Expert Rev Anticancer Ther 2013; 14:75-92. [DOI: 10.1586/14737140.2014.856273] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
289
|
Molecular epidemiology of human papillomavirus infections in cervical samples from cuban women older than 30 years. J Low Genit Tract Dis 2013; 18:210-7. [PMID: 24270200 DOI: 10.1097/lgt.0b013e3182a7bb89] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE This study aimed to provide information about the molecular epidemiology of human papillomavirus (HPV) in a group of Cuban women. MATERIALS AND METHODS DNA from cervical samples was analyzed using a quantitative real-time polymerase chain reaction (PCR), which detects 6 of the clinically most relevant high-risk HPV types. Furthermore, end point PCR and sequencing were performed. Three hundred twenty-two women (211 with positive and 111 with negative cytologic results) aged between 30 and 69 years were enrolled. Risk factors associated with HPV infections and premalignant lesions were also investigated. RESULTS HPV DNA was detected in 76.1% (245/322) of the studied population, and 34 different genotypes were found. There was an association between HPV infection and low educational level, history of oral contraceptives, menopausal stage, as well as cigarette and/or alcohol consumption. Besides, in a multivariate analysis, previous positive Pap test result and positive colposcopy finding were both predictor variables for HPV infections and for premalignant lesions. Human papillomavirus infection was found in 94.3% of women (199/211) with positive cytologic result and in 41.4% (46/111) of those with negative results, being more likely that the first group was infected with any HPV (odds ratio = 23.43; 95% CI = 11.70-46.92; p = .000). The most common genotypes were HPV types 16, 18, 31, 58, 33, and 45. All the cases with HPV positive findings had at least 1 high-risk HPV genotype. CONCLUSIONS This is the first report of the molecular epidemiology of HPV in Cuban women, based on results from a DNA sequence and quantitative PCR. Most individuals were infected with high-risk HPV types. These findings support the inclusion of HPV vaccine in Cuba.
Collapse
|
290
|
Lim AWW, Forbes LJL, Rosenthal AN, Raju KS, Ramirez AJ. Measuring the nature and duration of symptoms of cervical cancer in young women: developing an interview-based approach. BMC WOMENS HEALTH 2013; 13:45. [PMID: 24219028 PMCID: PMC3835395 DOI: 10.1186/1472-6874-13-45] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Accepted: 11/08/2013] [Indexed: 11/10/2022]
Abstract
BACKGROUND Some young women experience delays in diagnosis of cervical cancer, but little research about ways of studying these delays has been published. A major challenge is that gynaecological symptoms are common in young women, but cervical cancer is rare. This study describes the development and testing of a measure for studying delays in diagnosis in young women with cervical cancer. METHODS Prospective development of an interview measure and testing of its ability to reliably and systematically collect relevant data in two large hospitals in London, UK using 27 women aged 18-40 diagnosed with cervical cancer in the previous two years. We developed a semi-structured interview schedule and data extraction form to systematically collect data on symptoms (including nature and duration) and risk factors for delayed diagnosis from young women with cervical cancer. We piloted the measure among young women with cervical cancer (audiorecording it with their permission), refining it iteratively. To complete the measure, we developed a database for managing the data and a manual for using the schedule. Two researchers extracted data from the recorded interviews to assess inter-rater reliability. RESULTS The final interview schedule yielded quantitative data on the nature and duration of symptoms and risk factors for delayed diagnosis. Inter-rater reliability was high. In the pilot, 12 of the 27 women were diagnosed via symptomatic presentation. Median time from the symptom triggering presentation to presentation was one month (interquartile range 0-4 months). Median time from presentation to diagnosis was three months (interquartile range 1-8.5 months). CONCLUSIONS We have developed a reliable tool for measuring the nature and duration of symptoms in young women with cervical cancer. Pilot data suggest that a substantial proportion of women experience delay between first presentation and diagnosis.
Collapse
Affiliation(s)
- Anita W W Lim
- Kings College London Promoting Early Presentation Group, 9th Floor Capital House, 42 Weston Street, London SE1 3QD, UK.
| | | | | | | | | |
Collapse
|
291
|
Exploiting biospectroscopy as a novel screening tool for cervical cancer: towards a framework to validate its accuracy in a routine clinical setting. Bioanalysis 2013; 5:2697-711. [DOI: 10.4155/bio.13.233] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Biospectroscopy is an emerging field that harnesses the platform of physical sciences with computational analysis in order to shed novel insights on biological questions. An area where this approach seems to have potential is in screening or diagnostic clinical settings, where there is an urgent need for new approaches to objectively interrogate large numbers of samples in an objective fashion with acceptable levels of sensitivity and specificity. This review outlines the benefits of biospectroscopy in screening for precancer lesions of the cervix due to its ability to separate different grades of dysplasia. It evaluates the feasibility of introducing this technique into cervical screening programs on the basis of its ability to identify biomarkers of progression within derived spectra (‘biochemical‑cell fingerprints’).
Collapse
|
292
|
O'Brien KM, Sharp L. Trends in incidence of, and mortality from, cervical lesions in Ireland: baseline data for future evaluation of the national cervical screening programme. Cancer Epidemiol 2013; 37:830-5. [PMID: 24129395 DOI: 10.1016/j.canep.2013.09.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 08/25/2013] [Accepted: 09/02/2013] [Indexed: 11/15/2022]
Abstract
AIM To investigate incidence and mortality trends for cervical lesions in Ireland in the period 1994-2008. METHODS We used data from the National Cancer Registry, Ireland and national death registration data to calculate age-standardised rates for the periods of interest. We used standardised rate ratios to test whether incidence was associated with socio-demographic variables and used Joinpoint to examine trends by morphology grouping. RESULTS Incidence of cervical cancer and cervical intraepithelial neoplasia (CIN3) rose over the period 1994-2008. The annual percentage change for cervical cancer was 1.8% and that for CIN3 was 3.8%. Women resident in the most deprived areas had invasive cervical cancer incidence almost twice as high as those resident in the least deprived areas (standardised rate ratio (SRR)=1.8). Comparing incidence in Ireland to England and Wales, Northern Ireland and Scotland in the three years 2005-2007, the SRRs (other areas vs. Ireland) were 0.70, 0.88 and 0.84 respectively. Cervical cancer rates have fallen in these countries in the same period that there is a rise demonstrated in Ireland. CONCLUSION Incidence rates of cervical cancer rose in Ireland steadily, albeit modestly, during 1994-2008, most likely due to long-term changes in patterns of sexual behaviour and contraceptive use. A more pronounced rise in CIN3 rates point to considerable levels of opportunistic screening during this period. Mortality rates have changed little over the past four decades, in contrast to trends in countries with well-organised screening programmes.
Collapse
Affiliation(s)
- Katie M O'Brien
- National Cancer Registry, Building 6800, Airport Business Park, Kinsale Road, Cork, Ireland.
| | | |
Collapse
|
293
|
Osazuwa-Peters N. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy? Vaccine 2013; 31:5500-5. [PMID: 24095883 DOI: 10.1016/j.vaccine.2013.09.031] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 09/16/2013] [Indexed: 12/18/2022]
Abstract
BACKGROUND Human papillomavirus (HPV) is a sexually transmitted infection (STI) of global importance; it is the most prevalent STI in the United States, with strains causally linked to oropharyngeal and other cancers. Efforts to prevent HPV have been made to varying degrees by policies implemented by different state governments; however, HPV and associated oropharyngeal cancer continue to show increasing incidence rates in the US. DESIGN A narrative review based on search on SciVerse, PubMed/Medline, Google Scholar, and EMBASE databases, as well as literature/documents from the World Health Organization, Centers for Disease Control and Prevention, American Cancer Society, National Conference of State legislatures, and the U.S. Department of Health and Human Services relevant to HPV and HPV vaccine policy in the US. RESULTS Vaccination has proved to be a successful policy in the US, and an extant recommendation aimed at preventing HPV and associated cervical and other anogenital cancers is the routine use of HPV vaccines for males and females. However, HPV vaccines are presently not recommended for preventing oropharyngeal cancer, although they have been shown to be highly effective against the HPV strains that are most commonly found in the oropharynx. And while there is a history of successful vaccine mandate in the US with resulting decrease in occurrence of infectious diseases, implementing HPV vaccine mandate has proved to be very unpopular. CONCLUSIONS With emerging evidence of the efficacy of the use of the HPV vaccine in preventing oral-HPV, more focus should be put on extending HPV vaccine to present oral HPV infection and oropharyngeal cancer. Also, implementing a broader HPV vaccine policy that include mandating HPV vaccines as a school-entry requirement for both sexes may increase vaccine use in the US for the greater good of the public.
Collapse
Affiliation(s)
- N Osazuwa-Peters
- Cancer Center, Saint Louis University, St. Louis, MO 63110, USA.
| |
Collapse
|
294
|
de Almeida FG, Machado AP, Fernandes CEDS, Ferreira AT, Padovani CTJ, Tozetti IA. Molecular epidemiology of the human papillomavirus infection in self-collected samples from young women. J Med Virol 2013; 86:266-71. [PMID: 24009072 DOI: 10.1002/jmv.23725] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2013] [Indexed: 11/12/2022]
Abstract
The prevalence of human papillomavirus (HPV) infection is the highest in young, sexually active women less than 35 years of age. Direct diagnosis of infection by enabling genotyping methods is important considering that the viral types are divided into high (HR-HPV) and low (LR-HPV) oncogenic risk. This study aimed to evaluate the epidemiological and molecular characteristics of HPV infection in self-collected samples from young women. A cross-sectional study of 245 sexually active students (18 to 35 years of age) was undertaken with self-collected samples. Extracted DNA was analyzed by polymerase chain reaction (PCR) with the PGMY 09/11 and PC04/GH20 primers for the detection of HPV DNA and the β-globin gene, respectively. Viral genotyping was performed by type-specific PCR (TS-PCR) and restriction fragment length polymorphism (RFLP). Of the 236 valid samples, 68 (28.9%) were positive for HPV DNA, as genotyped by TS-PCR and RFLP. The HR-HPV were most prevalent, especially HPV-16, -31, -33, and -45, and the most prevalent LR-HPV were HPV-6 and -83. Multi-type HPV infections were detected in 17 (25%) samples. HPV infection was statistically more prevalent among younger women with lower educational levels and who had more partners in the past 2 years. A high prevalence of HPV infection was found in the age group examined, especially HR-HPV types, as well as the presence of risk behaviors associated with HPV infection were observed. Considering these results, vaccinating females before the onset of sexual activity in Brazil should be emphasized.
Collapse
Affiliation(s)
- Flávia Gatto de Almeida
- Program of Infectious and Parasitary Diseases from Medicine School, Universidade Federal de MatoGrosso do Sul/UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | | | | | | | | | | |
Collapse
|
295
|
hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy. Br J Cancer 2013; 109:1766-74. [PMID: 24008667 PMCID: PMC3790172 DOI: 10.1038/bjc.2013.519] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 07/31/2013] [Accepted: 08/09/2013] [Indexed: 11/11/2022] Open
Abstract
Background: The follow-up after abnormal Pap smear and negative colposcopy is not clearly defined. This study aimed at investigating the role of hr-HPV testing in the management of abnormal Pap test and negative colposcopy for Cervical Intraepithelial Neoplasia grade 2 or worse (CIN2+). Methods: The study enroled 1029 women with abnormal screening cytology (years 2006–2010) and negative colposcopy for CIN2+, which subsequently performed a hr-HPV test. Incident CIN2+ lesions were identified through linkage with cancer registry, hospital discharge records, neoplastic pathology reports and the archive of screening programme (2006–2011). Results: During the follow-up, the cohort developed 133 CIN2+ lesions; only one among hr-HPV-negative women. The probability of developing CIN2+ on follow-up time was 0.44% (95% confidence interval (CI) 0.1–3.1) and 41.8% (95% CI 31.8–53.5) for hr-HPV-negative women and hr-HPV-positive women, respectively. A woman with a positive hr-HPV test had about 105 times higher probability of developing a CIN2+ lesion than a woman with a negative hr-HPV test (hazard ratio (HR)=104.5, 95% CI 14.5–755.1), adjusted for index Pap test result, age and cervix squamocolumnar junction visualisation. Conclusion: Our results confirm that hr-HPV testing is able to select the real group of women at risk of developing CIN2+ lesions in the follow-up of abnormal cytology and first negative colposcopy.
Collapse
|
296
|
High-Risk Human Papillomavirus (Hpv) Infection in Women Undergoing in Vitro Fertilization / Okužbe Z Visokorizičnimi Genotipi Humanih Papilomskih Virusov (Hpv) Pri Ženskah, Vključenih V Postopke Zunajtelesne Oploditve. Zdr Varst 2013. [DOI: 10.2478/sjph-2013-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Objective: The aim of our study was to establish the prevalence of high-risk human papillomavirus (hr-HPV) infection in a population of women included in an in vitro fertilisation (IVF) program and to correlate the outcome of IVF cycles with HPV status.
Methods: A total of 195 women undergoing the IVF program were included in the study. A cervical smear for cytological analysis and hr-HPV determination was collected from every woman. RealTime High Risk HPV test (Abbott Molecular Inc., Des Plaines, IL) has been used for the detection of hr-HPV infection. All participants were invited to complete an anonymous questionnaire that included questions regarding medical and sexual history as well as risk factors for HPV infection. HPV 16 and HPV 18 positive women were invited for follow-up gynaecological examinations, including colposcopy 4 to 6 months after the inclusion.
Results: Mean age of included infertile women was 33.7 ± 4.36 years. A total of 16/195 women (8.2%) were hr-HPV positive. Hr-HPV infection was not associated with the percentage of mature oocytes, the percentage of fertilised oocytes, with embryo quality or with pregnancy rate in our study.
Conclusions: The prevalence of hr-HPV genotypes in Slovenian infertile women undergoing IVF is lower than the hr-HPV prevalence in the general population. We were unable to find an association between hr-HPV cervical infection and the outcome of IVF cycles.
Collapse
|
297
|
Petry KU, Rinnau F, Böhmer G, Hollwitz B, Luyten A, Buttmann N, Brünger M, Iftner T. Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. BMC Cancer 2013; 13:379. [PMID: 23937771 PMCID: PMC3751119 DOI: 10.1186/1471-2407-13-379] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Accepted: 08/01/2013] [Indexed: 11/17/2022] Open
Abstract
Background Primary human papilloma virus (HPV) screening is more effective than cytology in reducing the risk of cervical cancer, but screening intervals should be extended in HPV-negative women. However, some Markov models predicted that long intervals are associated with an excess risk of cervical cancer. The aim of this analysis was to estimate the real-life risks and benefits of annual Papanicolaou (Pap) screening in HPV-negative women with normal cytology. Methods Women with negative Hybrid Capture 2 (HC2) results and normal cytology at the time of inclusion in the Hannover HPV screening trial underwent annual Pap smears for 5 years. A subgroup was randomly selected for retesting with cytology, HC2, and colposcopy 60–68 months after recruitment. Results Of 4236 women included, 3406 had at least one Pap smear, but only 1185 attended all five annual screening visits. The proportion of women with at least one abnormal smear was 14.4% in 60 months. The probability of abnormal smears increased continuously over time. No case of ≥ CIN2+ was observed during 5 years. Of 605 women selected for subgroup analysis, 292 agreed to be retested (48.3%). The rate of high-risk HPV at 60–68 months was 3.0% (9/296). Conclusions The long-term risk of high-grade neoplasia after an initial negative HC2 test and normal cytology result was low, while the rate of false-positive abnormal Pap smears was significant and increased constantly over time. Pap smear screening of HPV-negative women more frequently than every 5 years could be potentially harmful and seems to be of little clinical value.
Collapse
Affiliation(s)
- Karl Ulrich Petry
- Zentrum für Frauenheilkunde, Medizinische Hochschule Hannover (MHH), Carl-Neuberg-Street 1, 30625 Hannover, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
298
|
Moss EL, Arbyn M, Dollery E, Leeson S, Petry KU, Nieminen P, Redman CWE. European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013; 170:255-8. [PMID: 23891389 DOI: 10.1016/j.ejogrb.2013.06.032] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 05/11/2013] [Accepted: 06/23/2013] [Indexed: 10/26/2022]
Abstract
OBJECTIVE Optimization of colposcopy practice requires a program of quality assurance including the monitoring of performance indicators. The European Federation of Colposcopy (EFC) aimed to identify a list of quality indicators for colposcopic practice, which are relevant, reproducible and practical across all of the member countries. STUDY DESIGN A five-round Delphi consultation was conducted in 30 full, 5 associate and 4 potential member countries in order to determine a core list of quality indicators including optimal target ranges. RESULTS Six indicators were selected from a list of 37 proposed standards. Two further rounds of consultation were conducted to determine expert opinion on the target level for each of the standards. The six indicators identified and corresponding targets were: documentation of whether or not the squamocolumnar junction has been seen (100%); colposcopy prior to treatment for abnormal cervical cytology (100%); percentage of excisional treatments/conizations to contain cervical intra-epithelial neoplasia grade two or worse (≥85%); percentage of excised lesions/conizations with clear margins (≥80%); and two indicators concerned the number of cases to be colposcoped per year: ≥50 low-grade/minor and ≥50 high-grade/major cytological abnormalities. CONCLUSIONS A Delphi consultation identified six EFC quality indicators. These are a first step in an international attempt to optimize colposcopy practice throughout Europe. The current targets are based on expert opinion and may need adaptation in the future. Data are needed from European colposcopy settings to determine whether the indicators are achievable practice-based benchmarks and will help in improving and fine tuning the list of performance indicators and targets.
Collapse
Affiliation(s)
- Esther L Moss
- Department of Gynaecological Oncology, University Hospitals of Leicester, Leicester, UK
| | | | | | | | | | | | | |
Collapse
|
299
|
Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J Clin Virol 2013; 58:155-60. [PMID: 23867008 DOI: 10.1016/j.jcv.2013.06.029] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 06/10/2013] [Accepted: 06/23/2013] [Indexed: 11/21/2022]
Abstract
BACKGROUND Many cervical cancers occur among women who have not attended cervical screening. Strategies to reach non-attending women may improve the effectiveness of cervical screening programmes. OBJECTIVE To compare the responses among long-term non-attending women to either (i) HPV-testing of a self-collected vaginal sample, or (ii) cytological screening with a flexible no-fee appointment for sampling at an outpatient clinic. STUDY DESIGN Among the 242,000 women aged 32-65 years in Southern Sweden, we identified 28,635 women who had not had any cervical smears taken for >9 years. We randomized 1000 women to invitation to HPV self-sampling, and 500 women to flexible outpatient clinic appointments. Responding women received a questionnaire about their reasons for previous non-attendance. RESULTS The response rate to HPV self-sampling was three times higher than the flexible outpatient clinic invitations (147/1000 women (14.7%) compared to 21/500 (4.2%) p<0.0001). High-risk (hr)-HPV was found in 10/147 self-sampled women (6.9%). 7/10 hr-HPV-positive women attended colposcopy, but no HSIL was found. Among the clinic-sampled women, 2/21 had hr-HPV and 1/21 had HSIL. Reasons for not attending were "uncomfortable with vaginal examination", "feel healthy", "lack of time" and "experience of unfriendly health workers". CONCLUSIONS Although the response rate was low for both interventions, the invitation to vaginal HPV self-sampling was more effective for increasing the coverage of the screening programme. The fact that "uncomfortable with vaginal examination" was the most common reason for non-attending suggests that self-sampling could be further explored as a strategy to increase the coverage of cervical screening programmes.
Collapse
|
300
|
García-Garrido AB, Vázquez-Rodríguez JA, Grande-González E, Ramos-Barrón MÁ. [Coverage and costs of opportunistic screening for cervical cancer in Cantabria (Spain)]. GACETA SANITARIA 2013; 28:14-9. [PMID: 23845269 DOI: 10.1016/j.gaceta.2013.05.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Revised: 05/22/2013] [Accepted: 05/27/2013] [Indexed: 10/26/2022]
Abstract
OBJECTIVE To analyze cervical cancer screening performed in Cantabria by evaluating the coverage and costs of screening and by calculating the available direct costs of the disease and the indirect costs of cervical cancer mortality. METHODS Screening for cervical cancer is performed in women aged between 21 and 65. According to the census for 2011 in Cantabria, there were 189.111 women in this age group. We performed a cross sectional, quantitative and qualitative study of the Pap smears performed and analyzed the direct and indirect costs of cervical cancer. RESULTS Between 2006 and 2011, 51% of women studied had one Pap smear, and 26% had two. In 2011, 31.554 Pap smears were performed in opportunistic screening in Cantabria, and the direct cost was 2,904.760 €. The annual direct cost of cervical cancer (average 2008-2010) was 567.567 €. The annual indirect costs (average 2001-2008) of cervical cancer was 386.122.02 €, in the reference scenario considered. CONCLUSIONS Only 26% of women in Cantabria attended screening within the intervals recommended in the current opportunistic protocol. The cost data provided in this study may be useful for future economic evaluations.
Collapse
Affiliation(s)
- Ana Belén García-Garrido
- Centro de Salud de Suances, Gerencia de Atención Primaria, Servicio Cántabro de Salud, Suances (Cantabria), España
| | - José Andrés Vázquez-Rodríguez
- Servicio de Oncología Radioterápica, Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud, Santander, Cantabria, España
| | - Elena Grande-González
- Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud, Santander, Cantabria, España
| | - María Ángeles Ramos-Barrón
- Servicio de Urgencias de Atención Primaria de Torrelavega, Gerencia de Atención Primaria, Servicio Cántabro de Salud, Torrelavega (Cantabria), España.
| |
Collapse
|